Filing summary
Entity discrepancy: The request identifies Skyai, Inc., but the supplied Form 10-Q is for Sharps Technology, Inc. (Nasdaq: STSS, STSSW). This summary covers Sharps Technology’s unaudited quarter ended March 31, 2023, compared with the quarter ended March 31, 2022 where applicable.
Business context and reporting period
Sharps is a pre-revenue medical-device company developing patented safety syringes and pursuing commercialization through manufacturing and distribution. It acquired the Safegard manufacturing facility in Hungary in July 2022. The company says it has generated no revenue to date and has incurred recurring losses.
Financial performance and position
| Metric | Q1 2023 / March 31, 2023 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q1 2022 |
| Operating expenses | $2.318 million | $1.337 million in Q1 2022 |
| Net loss | $2.112 million | $1.870 million in Q1 2022 |
| Loss per share, basic and diluted | $0.20 | $0.36 in Q1 2022 |
| Cash and cash equivalents | $5.257 million | $4.171 million at December 31, 2022 |
| Working capital | $3.555 million | $2.417 million at December 31, 2022 |
| Total liabilities | $2.564 million | $2.199 million at December 31, 2022 |
| Stockholders’ equity | $10.967 million | $9.641 million at December 31, 2022 |
Gross margin is not applicable because the company reported no revenue. Operating cash use was $2.063 million, versus $1.216 million in Q1 2022; investing cash use was $163,272, and financing provided $3.239 million, principally from the February equity offering. Cash increased by $1.086 million during the quarter. The company reported no notes payable at March 31, 2023; the $2 million bridge notes were repaid with IPO proceeds in April 2022. Current liabilities included $1.423 million of warrant liabilities.
Material changes versus Q1 2022
- Net loss increased $242,109, or 13%. G&A rose $1.153 million to $1.984 million, reflecting higher payroll and consulting, stock compensation, marketing, insurance, public-company and investor-relations costs.
- R&D declined $172,487 to $333,888. The prior-year period included $275,000 of Safegard facility operating costs before the acquisition; 2023 included higher materials and depreciation related to product and equipment activity.
- Interest income of $36,792 replaced $245,437 of interest expense, largely because the prior-year expense related to bridge financing that was later repaid.
- A $184,085 gain from warrant fair-value changes partially offset operating losses; warrant remeasurement can cause earnings volatility.
- The February 2023 offering raised approximately $3.2 million net of approximately $600,000 in fees. It issued 2,248,521 common shares and an equal number of five-year warrants exercisable at $1.56.
Outlook, risks and unusual items
- No numerical revenue, profit, or cash-flow guidance is provided. Management expects continued R&D spending and says inventory is being built to support commercialization; delivery is expected shortly after orders are received.
- A four-year agreement with Nephron Pharmaceuticals runs through September 2026, with renewal provisions. Nephron is the exclusive U.S. distributor under a separate distribution agreement. The companies describe plans for product development, pharma services and potential U.S. manufacturing expansion; the filing describes projected product supply beginning in mid-2023, not a guarantee of sales.
- Inventory increased to $546,720 from $185,804 at year-end. The company also reported $521,257 in outstanding equipment, mold and component purchase orders, including advance payments.
- Potential dilution is significant: 11,296,316 warrants were outstanding at March 31, alongside stock options; 13,679,438 options and warrants were excluded from diluted loss per share as anti-dilutive. The company reported 11,655,936 common shares outstanding as of May 15, 2023.
- The company remains pre-revenue with an accumulated deficit of $17.419 million and continuing operating cash use. Its cash position depends in part on financing proceeds; the filing gives no explicit cash-runway estimate.
- A 2% royalty on net sales of products related to specified intellectual property remains in place. The filing reports preliminary settlement discussions after the company terminated a former executive’s employment agreement effective May 1, 2023. No material litigation or other material loss contingencies were reported.
- Management stated that disclosure controls were effective as of quarter-end and reported no material change in internal control over financial reporting. The filing says no material risk-factor changes from the 2022 Form 10-K.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Sharps Technology, Inc., not Skyai, Inc.
- Reconcile the cash-at-year-end figures: the balance sheet reports $4,170,897 at December 31, 2022, while the MD&A narrative reports $4,107,897.
- Track Nephron agreement execution, product readiness, regulatory or standards compliance, actual orders, and whether projected supply began as planned.
- Assess cash burn, available liquidity and the timing and terms of any additional financing, alongside planned manufacturing and equipment commitments.
- Review potential share dilution from warrants, options and future equity raises, and monitor warrant-liability fair-value effects on reported earnings.